As of 2025-02-18, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -37.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 157.23 mil USD. VNDA's TTM EBITDA according to its financial statements is -4.20 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Range | Selected | |
Trailing P/E multiples | 11.9x - 15.5x | 13.8x |
Forward P/E multiples | 17.1x - 22.4x | 20.2x |
Fair Price | 0.86 - 4.85 | 2.63 |
Upside | -80.5% - 9.8% | -40.4% |
Date | EV/EBITDA |
2025-02-14 | -37.39 |
2025-02-13 | -41.27 |
2025-02-12 | -41.97 |
2025-02-11 | -41.55 |
2025-02-10 | -40.17 |
2025-02-07 | -42.66 |
2025-02-06 | -41.14 |
2025-02-05 | -38.92 |
2025-02-04 | -38.22 |
2025-02-03 | -35.87 |
2025-01-31 | -37.25 |
2025-01-30 | -39.61 |
2025-01-29 | -38.92 |
2025-01-28 | -37.67 |
2025-01-27 | -37.81 |
2025-01-24 | -37.11 |
2025-01-23 | -37.39 |
2025-01-22 | -36.42 |
2025-01-21 | -38.64 |
2025-01-17 | -36.56 |
2025-01-16 | -37.67 |
2025-01-15 | -37.81 |
2025-01-14 | -36.84 |
2025-01-13 | -38.92 |
2025-01-10 | -39.89 |
2025-01-08 | -40.58 |
2025-01-07 | -43.35 |
2025-01-06 | -42.52 |
2025-01-03 | -43.35 |
2025-01-02 | -42.94 |
2024-12-31 | -42.52 |
2024-12-30 | -42.38 |
2024-12-27 | -42.80 |
2024-12-26 | -42.80 |
2024-12-24 | -43.08 |
2024-12-23 | -41.00 |
2024-12-20 | -42.38 |
2024-12-19 | -40.30 |
2024-12-18 | -39.19 |
2024-12-17 | -41.69 |
2024-12-16 | -40.30 |
2024-12-13 | -40.03 |
2024-12-12 | -40.17 |
2024-12-11 | -40.86 |
2024-12-10 | -39.89 |
2024-12-09 | -42.94 |
2024-12-06 | -43.22 |
2024-12-05 | -42.38 |
2024-12-04 | -43.22 |
2024-12-03 | -44.19 |